Printer Friendly

TWO NEW MEMBERS TO JOIN BOARD OF FOUNTAIN PHARMACEUTICALS

 TWO NEW MEMBERS TO JOIN BOARD OF FOUNTAIN PHARMACEUTICALS
 LARGO, Fla., Sept. 25 /PRNewswire/ -- Fountain Pharmaceuticals, Inc. (NASDAQ: FPHI) announced today that two new members have been added to its board of directors.
 Joining the board of Fountain, effective as of today, are E. Donald Shapiro and Barry Cohen.
 Shapiro, a prominent legal scholar and consultant, civic leader and former dean of New York Law School, presently serves as a professor of law at New York Law School and is a member of the board of directors of Loral Corporation, Bank Leumi, Interferon Sciences, Inc. and other corporations.
 Cohen has extensive pharmaceutical experience, having served in various executive capacities for more than 30 years with Merck and Company, Inc., a worldwide leading pharmaceutical company, most recently as senior vice president. Prior to that, Cohen served as president of Merck Sharp & Dohme, International for more than 10 years. Cohen also is a member of the board of directors of Akzo, N.V.
 John C. Walsh, chief executive officer and president of the company, stated, "We are extremely pleased that individuals of the caliber of Messrs. Shapiro and Cohen have chosen to join our board of directors. It is our intention to draw upon the vast wealth of intellectual resources and business acumen made available by their participation on our board."
 Fountain Pharmaceuticals, Inc. is a development stage company that has specialized in the application of encapsulated drug delivery systems for the purposes of improving drug compound delivery and enhancing effectiveness of existing drug compound products. The company is currently reviewing opportunities for the development and marketing of a proprietary line of products with application in both the human health care and consumer goods industry.
 -0- 9/25/92
 /CONTACT: John C. Walsh of Fountain Pharmaceuticals, 813-392-5300/ CO: Fountain Pharmaceuticals, Inc. ST: Florida IN: MTC SU: PER


MK-LJ -- PH005 -- 3422 09/25/92 09:27 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 25, 1992
Words:314
Previous Article:GM ASSEMBLY PLANT SHUTDOWN UPDATE
Next Article:FLORIDA KEYS ELECTRIC COOPERATIVE ASSOCIATION ISSUES UPDATE
Topics:


Related Articles
PFIZER ANNOUNCES EXECUTIVE APPOINTMENTS.
ROBERTS PHARMACEUTICAL ELECTS TWO NEW DIRECTORS
SCHERING-PLOUGH HEALTHCARE PRESIDENT DAVID COLLINS ELECTED CHAIRMAN OF NDMA
REJEANGE NAMED TO HEAD STERLING WINTHROP PHARMACEUTICALS GROUP
FOUNTAIN PHARMACEUTICALS ANNOUNCES REORGANIZATION OF MANAGEMENT
FOUNTAIN ANNOUNCES COMPLETION OF MANAGEMENT REORGANIZATION; DR. FOUNTAIN TO REJOIN THE COMPANY
ROBERTS PHARMACEUTICAL CORPORATION ELECTS TWO NEW DIRECTORS
ARIAD ELECTS THREE NEW DIRECTORS; FORMER LILLY CEO JOINS ARIAD BOARD
CIBA'S U.S. HEAD RICHARD BARTH ANNOUNCES RETIREMENT
Fountain Pharmaceuticals, Inc. Announces The Sale Of $2.5 Million Of Convertible Preferred Stock And Changes In Board Membership

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters